Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

Corporate Profile

<< Back

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. We are advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Our partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. We have approximately 150 employees.

We are advancing our three product candidates using novel biomarker and genetic approaches that may increase the likelihood of clinical, regulatory and commercial success of our first-in-class therapies.

  • Betrixaban –  Betrixaban, which was granted a Fast track designation by the FDA, is a novel oral once-daily inhibitor of FXa in development for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use. Acute medically ill patients are those hospitalized for serious medical conditions, such as heart failure, stroke, infection and pulmonary disease. Learn More
  • Andexanet alfa – Andexanet alfa is being developed as a reversal agent for patients anticoagulated with an oral or injectable Factor Xa inhibitor who experience a serious uncontrolled bleeding event or who require urgent or emergent surgery. Designated a Breakthrough Therapy by the U.S. Food and Drug Administration. Currently being studied in ANNEXA-4, a Phase 3b/4 single-arm, open-label confirmatory study in patients receiving apixaban, rivaroxaban, edoxaban or enoxaparin (a low molecular weight heparin and indirect Factor Xa inhibitor) who present with an acute major bleed. Portola has commercial rights to andexanet alfa outside of Japan.Learn more.
  • Cerdulatinib (PRT2070) –  Oral, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor that uniquely inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies – the B-cell receptor pathway via Syk and key cytokine receptors via JAK Being developed to treat patients with hematologic cancers, specifically those who have relapsed or who have not responded to prior therapies. Portola has worldwide rights to develop and commercialize cerdulatinib. Learn more.